BSE Live
Dec 26, 16:01Prev. Close
2019.55
Open Price
2043.80
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
0.00 (0)
NSE Live
Dec 26, 15:55Prev. Close
2020.10
Open Price
2018.00
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
0.00 (0)
| Profit & Loss account of Glenmark Pharma (in Rs. Cr.) | Mar 15 | Mar 14 | Mar 13 | Mar 12 | Mar 11 | |
| 12 mths | 12 mths | 12 mths | 12 mths | 12 mths | ||
| INCOME | ||||||
| Revenue From Operations [Gross] | 5,199.63 | 2,411.36 | 2,033.85 | 1,615.82 | 1,212.25 | |
| Less: Excise/Sevice Tax/Other Levies | 200.42 | 137.80 | 98.57 | 69.00 | 58.70 | |
| Revenue From Operations [Net] | 4,999.21 | 2,273.56 | 1,935.29 | 1,546.82 | 1,153.55 | |
| Total Operating Revenues | 5,085.60 | 2,300.90 | 1,949.30 | 1,564.67 | 1,162.94 | |
| Other Income | 84.94 | 67.13 | 116.25 | 55.10 | 71.75 | |
| Total Revenue | 5,170.54 | 2,368.04 | 2,065.55 | 1,619.77 | 1,234.69 | |
| EXPENSES | ||||||
| Cost Of Materials Consumed | 1,564.03 | 467.89 | 415.75 | 337.67 | 240.49 | |
| Purchase Of Stock-In Trade | 173.95 | 159.97 | 141.09 | 104.95 | 87.16 | |
| Operating And Direct Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Changes In Inventories Of FG,WIP And Stock-In Trade | -69.65 | -5.23 | -3.67 | -12.86 | 13.99 | |
| Employee Benefit Expenses | 662.25 | 395.35 | 303.02 | 246.81 | 174.16 | |
| Finance Costs | 30.19 | 30.98 | 43.69 | 60.87 | 85.75 | |
| Depreciation And Amortisation Expenses | 119.46 | 30.20 | 25.04 | 21.11 | 20.99 | |
| Other Expenses | 1,290.03 | 786.96 | 760.67 | 577.13 | 361.37 | |
| Total Expenses | 3,770.26 | 1,866.11 | 1,685.60 | 1,335.67 | 983.90 | |
| Profit/Loss Before Exceptional, ExtraOrdinary Items And Tax | 1,400.28 | 501.92 | 379.95 | 284.10 | 250.79 | |
| Exceptional Items | -168.74 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Profit/Loss Before Tax | 1,231.55 | 501.92 | 379.95 | 284.10 | 250.79 | |
| Tax Expenses-Continued Operations | ||||||
| Current Tax | 280.17 | 108.02 | 65.70 | 55.40 | 67.40 | |
| Less: MAT Credit Entitlement | 52.69 | 47.76 | 65.70 | 37.47 | 28.62 | |
| Deferred Tax | -3.46 | 7.84 | 4.78 | 0.87 | -0.17 | |
| Tax For Earlier Years | 0.00 | 0.00 | -10.93 | 0.00 | 0.00 | |
| Total Tax Expenses | 224.02 | 68.10 | -6.15 | 18.80 | 38.62 | |
| Profit/Loss After Tax And Before ExtraOrdinary Items | 1,007.53 | 433.82 | 386.11 | 265.30 | 212.18 | |
| Profit/Loss From Continuing Operations | 1,007.53 | 433.82 | 386.11 | 265.30 | 212.18 | |
| Profit/Loss For The Period | 1,007.53 | 433.82 | 386.11 | 265.30 | 212.18 | |
| OTHER ADDITIONAL INFORMATION | ||||||
| EARNINGS PER SHARE | ||||||
| Basic EPS (Rs.) | 37.14 | 16.01 | 14.26 | 9.81 | 7.86 | |
| Diluted EPS (Rs.) | 37.13 | 16.00 | 14.25 | 9.80 | 7.85 | |
| VALUE OF IMPORTED AND INDIGENIOUS RAW MATERIALS STORES, SPARES AND LOOSE TOOLS | ||||||
| Imported Raw Materials | 359.92 | 33.54 | 31.41 | 20.58 | 9.17 | |
| Indigenous Raw Materials | 1,149.08 | 421.85 | 372.43 | 312.00 | 225.37 | |
| STORES, SPARES AND LOOSE TOOLS | ||||||
| Imported Stores And Spares | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Indigenous Stores And Spares | 55.02 | 12.50 | 11.91 | 5.10 | 5.95 | |
| DIVIDEND AND DIVIDEND PERCENTAGE | ||||||
| Equity Share Dividend | 54.26 | 54.25 | 54.17 | 54.11 | 10.81 | |
| Tax On Dividend | 11.35 | 9.24 | 9.23 | 8.78 | 1.85 | |
| Equity Dividend Rate (%) | 200.00 | 200.00 | 200.00 | 200.00 | 40.00 |
23.12.2025
04.12.2025
Glenmark Consolidated September 2025 Net Sales at Rs 6,046.87 crore, up 76.1% Y-o-Y
03.12.2025
24.11.2025
Glenmark Standalone September 2025 Net Sales at Rs 1,538.66 crore, down 41.63% Y-o-Y
04.12.2025
Glenmark Consolidated September 2025 Net Sales at Rs 6,046.87 crore, up 76.1% Y-o-Y
24.11.2025
Glenmark Standalone September 2025 Net Sales at Rs 1,538.66 crore, down 41.63% Y-o-Y
27.05.2025
Glenmark Standalone March 2025 Net Sales at Rs 2,009.49 crore, down 6.46% Y-o-Y
04.03.2025
Glenmark Consolidated December 2024 Net Sales at Rs 3,387.55 crore, up 35.14% Y-o-Y
08.07.2022
Glenmark Pharmaceuticals Q1 PAT may dip 41.8% YoY to Rs 178.4 cr: Prabhudas Lilladher
14.04.2022
Glenmark Pharmaceuticals Q4 PAT may dip 20.1% YoY to Rs 186.8 cr: Prabhudas Lilladher
13.01.2022
Glenmark Pharmaceuticals Q3 PAT seen up 17.8% YoY to Rs 292.4 cr: Prabhudas Lilladher
06.10.2021
Glenmark Pharmaceuticals Q2 PAT seen up 18.4% YoY to Rs 269.5 cr: Prabhudas Lilladher
31.05.2019
Glenmark Pharma wilts 3% on muted Q4 show, CLSA downgrades to sell
09.02.2018
Glenmark Pharma tanks 9% after disappointing Q3 earnings, US pricing pressure to continue
28.07.2017
31.07.2015